Clincosm LogoSign in Get a demo

Hepatocellular Carcinoma

Showing NaN - NaN of 94
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Beijing (1mg NWRD06 administered by electroporation, 4mg NWRD06 administered by

Recruiting
  • Hepatocellular Carcinoma
  • 1mg NWRD06 administered by electroporation
  • +2 more
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Oct 15, 2023

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

Hepatocellular Carcinoma Trial in China (Anlotinib HCl capsules, Penpulimab injection, Anlotinib HCl capsules -matching ,

Recruiting
  • Hepatocellular Carcinoma
  • Anlotinib hydrochloride capsules, Penpulimab injection
  • Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
  • Bengbu, Anhui, China
  • +66 more
May 15, 2023

Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib Plus Tislelizumab
  • Transarterial Chemoembolization(TACE)
  • Beijing, Beijing, China
    Nan Zhang
Apr 22, 2023

Hepatocellular Carcinoma, Biliary Tract Cancer Trial in Worldwide (MEDI5752, Bevacizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Biliary Tract Cancer
  • Birmingham, Alabama
  • +44 more
Mar 17, 2023

Hepatocellular Carcinoma Trial in Beijing (Autologous RAK cells)

Recruiting
  • Hepatocellular Carcinoma
  • Autologous RAK cells
  • Beijing, Beijing, China
    Beijing Hospital Center of Biotherapy
Feb 13, 2023

Hepatocellular Carcinoma Trial in Worldwide (Sitravatinib, Tislelizumab, sitravatinib-matching )

Not yet recruiting
  • Hepatocellular Carcinoma
  • Bengbu, Anhui, China
  • +81 more
Feb 1, 2023

Liver Tumor, Hepatocellular Carcinoma Trial in Guangzhou, Beijing, Shanghai (Microwave ablation)

Active, not recruiting
  • Liver Tumor
  • Hepatocellular Carcinoma
  • Microwave ablation
  • Guangzhou, Guangdong, China
  • +3 more
Jan 23, 2023

Hepatocellular Carcinoma Trial in Worldwide (Nivolumab, Ipilimumab, Sorafenib)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Tucson, Arizona
  • +209 more
Jan 17, 2023

Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 5, 2023

Liver and Biliary Cancer Patients Treated With PD-1 Combination

Active, not recruiting
  • Hepatocellular Carcinoma
  • Bile Duct Cancer
  • [68Ga]FAPI PET/CT and [18F]FDG PET/CT
  • Beijing, China
    Department of Nuclear Medicine, Peking Union Medical College Hop
Dec 14, 2022

Hepatocellular Carcinoma Trial in Worldwide (drug, other, procedure)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Mobile, Alabama
  • +182 more
Dec 1, 2022

Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma Trial in Worldwide (THOR-707, Pembrolizumab,

Active, not recruiting
  • Oesophageal Squamous Cell Carcinoma
  • +4 more
  • Duarte, California
  • +39 more
Oct 31, 2022

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Bevacizumab, Placebo)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Birmingham, Alabama
  • +213 more
Aug 19, 2022

Hepatocellular Carcinoma Trial in China, Japan (Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Beijing City, China
  • +39 more
Jul 25, 2022

Hepatocellular Carcinoma Trial in Worldwide (Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Birmingham, Alabama
  • +132 more
Jul 20, 2022

Solid Tumors, NSCLC, Renal Cell Carcinoma Trial in China (Lenvatinib + Envafolimab, Sunitinib)

Recruiting
  • Solid Tumors
  • +3 more
  • Benbu, Anhui, China
  • +22 more
Jun 28, 2022

Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in China (Observation)

Recruiting
  • Primary Liver Cancer
  • +3 more
  • Observation
  • Beijing, Beijing, China
  • +4 more
Jun 14, 2022

Hepatocellular Carcinoma Trial in Beijing (Camrelizumab, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Please Select, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jun 8, 2022

Hepatobiliary Tumors Tissue Samples Acquisition

Recruiting
  • Hepatocellular Carcinoma
  • +7 more
  • Gene expression analysis
  • +10 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jun 8, 2022

PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on

Recruiting
  • Hepatocellular Carcinoma
  • Acute Rejection
    • Beijing, Beijing, China
      Beijing Tsinghua Changgung Hospital
    Jun 6, 2022

    Hepatocellular Carcinoma Trial in Beijing (Rulonilimab+Lenvatinib, Rulonilimab +Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Jun 2, 2022

    Hepatocellular Carcinoma Trial in Beijing (Autologous memory lymphocyte Injection (NewishT), low-dose group, Autologous memory

    Recruiting
    • Hepatocellular Carcinoma
    • Autologous memory lymphocyte Injection (NewishT), low-dose group
    • Autologous memory lymphocyte Injection (NewishT), high-dose group
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    May 30, 2022

    Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

    Recruiting
    • Hepatocellular Carcinoma
    • SCG101
    • PD1/PD-L1 checkpoint inhibitor
    • Beijing, China
    • +3 more
    May 7, 2022